Back

Multimodal AI for Single cfDNA Profiling and Cancer Screening

Wang, B.; Song, L.; Li, H.; Lin, N.; Xin, Y.; He, X.; Liu, W.; Liu, L.; Cui, J.; Li, X.; Mei, Y.; You, Q.; Zhu, H.; Zhao, G.; Chen, G.; Liu, J.; Zhu, B.; Sun, X.; Wu, X.; Gao, Z.; Ye, Y.

2025-12-30 bioinformatics
10.64898/2025.12.29.696856 bioRxiv
Show abstract

Cell-free DNA (cfDNA) serves as a non-invasive biomarker for cancer detection, but conventional methods face challenges due to the ultra-low abundance of tumor-derived cfDNA (ctDNA) among normal cfDNA. Though nucleosome-bound cfDNA harbors rich epigenomic features that could enable ctDNA identification by single-molecule multi-omics cross-validation, this remains unexplored due to methodological limits. Here, we developed a cfDNA sequencing approach integrating methylation, fragmentomics, and histone modifications at the single-molecule level; together with gene semantics and epigenomic annotations, these modalities were vectorized and fused to represent each cfDNA molecule. We trained a Transformer-based model (cfAI) to profile and evaluate ctDNA likelihood at molecule, gene, and sample levels. cfAI achieved [~]10-fold enrichment of cancer-derived signals over noise and reached 72.6% sensitivity at 93.1% specificity for multi-cancer detection. Our study establishes an innovative framework that overcomes the inherent signal-to-noise limitations of conventional assays and reveals biological features at molecular resolution for cancer detection.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.